ML216 Prevents DNA Damage-Induced Senescence by Modulating DBC1-BLM Interaction

Area of Science:

• Molecular Biology
• Cellular Biology
• Aging Research

Background:

• DNA damage is a known inducer of cellular senescence and apoptosis.
• The precise mechanisms by which DNA-damaged cells transition to senescence are not fully understood.
• The role of DBC1 (Deleted in Breast Cancer 1) and BLM (Bloom syndrome helicase) in this process requires further elucidation.

Purpose of the Study:

• To investigate the role of DBC1 in regulating senescence following DNA damage.
• To explore the interaction between DBC1, BLM, and the process of senescence.
• To evaluate the therapeutic potential of ML216 in mitigating senescence and related conditions.

Main Methods:

• Utilized DBC1-deficient cells to assess senescence and apoptosis levels after DNA damage.
• Investigated the degradation of BLM protein during DNA damage.
• Examined the effect of ML216 on DBC1-BLM interaction and BLM stability.
• Assessed pulmonary function and levels of senescence and fibrosis in aged mice and a bleomycin-induced pulmonary fibrosis model.

Main Results:

• DNA damage induced higher levels of senescence in DBC1-deficient cells compared to apoptosis.
• BLM protein degradation was observed during DNA damage, correlating with p21 expression and senescence.
• DBC1 was found to bind and protect BLM from degradation, thereby suppressing senescence.
• ML216 was shown to promote the DBC1-BLM interaction, preserving BLM and suppressing senescence.
• ML216 treatment improved pulmonary function and reduced senescence and fibrosis in mouse models.

Conclusions:

• DBC1-mediated protection of BLM from degradation is a key mechanism preventing DNA-damaged cells from entering senescence.
• ML216 enhances this protective mechanism, offering a potential therapeutic strategy for senescence-related diseases.
• Targeting the DBC1-BLM interaction with ML216 shows promise for treating conditions like idiopathic pulmonary fibrosis.